New evidence demonstrates early use of Stalevo improves quality of life and may provide long-term benefits in patients with Parkinson's disease

Kyoto, October 31, 2006 - New data shows that Stalevo significantly improves quality of life in patients with Parkinson's disease with no or minimal motor fluctuations, when compared to traditional levodopa therapy. In addition, new analysis suggests that patients treated earlier with enhanced levodopa therapy experienced an immediate and sustained improvement in symptom control that was not achieved when treatment was delayed by 6 months. The new findings were presented today at the Movement Disorder Society's (MDS) 10th International Congress of Parkinson's Disease and Movement Disorders in Kyoto, Japan.

Press Release